Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EBITDA Margin for 16 consecutive years, with 78.57% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 1054.0% year-over-year to 78.57%, compared with a TTM value of 81.63% through Sep 2025, up 39.0%, and an annual FY2024 reading of 107.5%, down 6187.0% over the prior year.
  • EBITDA Margin was 78.57% for Q3 2025 at China Pharma Holdings, down from 49.53% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.81% in Q1 2023 and bottomed at 160.4% in Q2 2024.
  • Average EBITDA Margin over 5 years is 65.62%, with a median of 60.96% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -7441bps in 2024, then surged 11087bps in 2025.
  • Year by year, EBITDA Margin stood at 28.97% in 2021, then decreased by -28bps to 37.0% in 2022, then plummeted by -39bps to 51.46% in 2023, then plummeted by -145bps to 125.87% in 2024, then surged by 38bps to 78.57% in 2025.
  • Business Quant data shows EBITDA Margin for CPHI at 78.57% in Q3 2025, 49.53% in Q2 2025, and 68.47% in Q1 2025.